JP2017534583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534583A5 JP2017534583A5 JP2017515756A JP2017515756A JP2017534583A5 JP 2017534583 A5 JP2017534583 A5 JP 2017534583A5 JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017534583 A5 JP2017534583 A5 JP 2017534583A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- inhibitor
- gap junction
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 95
- 229940122194 Gap junction inhibitor Drugs 0.000 claims description 87
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 201000011510 cancer Diseases 0.000 claims description 66
- 239000003112 inhibitor Substances 0.000 claims description 43
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 42
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims description 39
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 31
- 102100034941 Protocadherin-7 Human genes 0.000 claims description 31
- 101710141460 Protocadherin-7 Proteins 0.000 claims description 31
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 102000001045 Connexin 43 Human genes 0.000 claims description 27
- 108010069241 Connexin 43 Proteins 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 24
- 210000004556 brain Anatomy 0.000 claims description 20
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 190000008236 carboplatin Chemical group 0.000 claims description 14
- 229960004562 carboplatin Drugs 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical group CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 13
- 229940013798 meclofenamate Drugs 0.000 claims description 13
- 102000010970 Connexin Human genes 0.000 claims description 12
- 108050001175 Connexin Proteins 0.000 claims description 12
- 210000003976 gap junction Anatomy 0.000 claims description 12
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 9
- 230000001394 metastastic effect Effects 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 98
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000009286 beneficial effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052966P | 2014-09-19 | 2014-09-19 | |
| US62/052,966 | 2014-09-19 | ||
| PCT/US2015/051057 WO2016044790A1 (en) | 2014-09-19 | 2015-09-18 | Methods for treating brain metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534583A JP2017534583A (ja) | 2017-11-24 |
| JP2017534583A5 true JP2017534583A5 (enExample) | 2018-10-25 |
| JP6898848B2 JP6898848B2 (ja) | 2021-07-07 |
Family
ID=55533931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515756A Active JP6898848B2 (ja) | 2014-09-19 | 2015-09-18 | 脳転移を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10413522B2 (enExample) |
| EP (2) | EP3685832B1 (enExample) |
| JP (1) | JP6898848B2 (enExample) |
| CN (1) | CN107106544B (enExample) |
| AU (3) | AU2015317330B2 (enExample) |
| CA (1) | CA2961894C (enExample) |
| WO (1) | WO2016044790A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6898848B2 (ja) * | 2014-09-19 | 2021-07-07 | メモリアル スローン ケタリング キャンサー センター | 脳転移を治療するための方法 |
| CN107290438B (zh) * | 2016-03-31 | 2020-10-16 | 深圳翰宇药业股份有限公司 | 一种多肽有关物质的高效液相色谱分析方法 |
| AU2018300007A1 (en) * | 2017-07-10 | 2020-02-27 | Cornell University | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment |
| CA3072087A1 (en) * | 2017-08-11 | 2019-02-14 | Board Of Regents, The University Of Texas System | Targeting kinases for the treatment of cancer metastasis |
| US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
| CA3154499A1 (en) * | 2019-09-13 | 2021-03-18 | Auckland Uniservices Limited | Compositions and methods for rescuing retinal and choroidal structure and function |
| CN111420025B (zh) * | 2020-04-28 | 2021-06-11 | 中国药科大学 | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 |
| GB202014831D0 (en) | 2020-09-21 | 2020-11-04 | Dc Europa Ltd | Disconnection agents |
| US12306192B2 (en) * | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| JP2025500876A (ja) * | 2021-12-14 | 2025-01-15 | トラスティーズ オブ タフツ カレッジ | 神経膠芽腫を含む癌の治療のための過分極性剤単独及び他の治療剤との組合せにおける使用 |
| CN114252324B (zh) * | 2022-03-02 | 2022-05-13 | 中国人民解放军军事科学院军事医学研究院 | 一种方便使用的多孔脑片孵育装置 |
| US20260034158A1 (en) * | 2022-07-20 | 2026-02-05 | The University Of North Carolina At Chapel Hill | Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine |
| WO2025024284A1 (en) * | 2023-07-21 | 2025-01-30 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against pcdh7 for lung cancer therapy |
| CN117298143A (zh) * | 2023-10-11 | 2023-12-29 | 广州医科大学附属第一医院（广州呼吸中心） | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034547A1 (en) | 1994-06-10 | 1995-12-21 | Smithkline Beecham Plc | C-4 amide substituted compounds and their use as therapeutic agents |
| GB9411635D0 (en) | 1994-06-10 | 1994-08-03 | Smithkline Beecham Plc | Novel treatment |
| DE69833791D1 (de) | 1997-11-24 | 2006-05-04 | Scripps Research Inst | Hemmer der "gap junction communication" |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6251931B1 (en) | 1998-11-24 | 2001-06-26 | The Scripps Research Institute | Inhibitors of gap junction communication |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6770633B1 (en) | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| US20060058379A1 (en) | 2002-11-29 | 2006-03-16 | Yasuyuki Kita | Connexin 26 inhibitor and cancer metastasis inhibitors |
| CN1852721B (zh) * | 2003-07-31 | 2013-03-27 | 得克萨斯大学体系董事会 | 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法 |
| DK1959981T3 (da) | 2005-02-03 | 2020-01-27 | Coda Therapeutics Ltd | Anti-connexin 43 forbindelser til behandling af kroniske sår |
| WO2008127251A1 (en) | 2006-05-05 | 2008-10-23 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Reversible inhibition of pyramidal gap junction activity |
| CA2710232A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
| US20130281524A1 (en) * | 2008-06-05 | 2013-10-24 | Peter Blower | Novel treatments |
| US8859615B2 (en) * | 2008-08-27 | 2014-10-14 | Samuel J. Danishefsky | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases |
| FR2935611B1 (fr) * | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| WO2011057199A1 (en) * | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| EP2506847A1 (en) | 2009-12-03 | 2012-10-10 | Proximagen Limited | Treatment of infectious diseases |
| JP2013512887A (ja) * | 2009-12-03 | 2013-04-18 | プロキシマゲン リミテッド | 感染症の治療 |
| WO2014129914A1 (en) * | 2013-02-22 | 2014-08-28 | Auckland Uniservices Limited | Methods of treatment |
| US9840533B2 (en) * | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2015057862A1 (en) * | 2013-10-15 | 2015-04-23 | President And Fellows Of Harvard College | Methods and compositions for eradicating leukemic cells |
| JP6898848B2 (ja) * | 2014-09-19 | 2021-07-07 | メモリアル スローン ケタリング キャンサー センター | 脳転移を治療するための方法 |
-
2015
- 2015-09-18 JP JP2017515756A patent/JP6898848B2/ja active Active
- 2015-09-18 CN CN201580063121.3A patent/CN107106544B/zh active Active
- 2015-09-18 WO PCT/US2015/051057 patent/WO2016044790A1/en not_active Ceased
- 2015-09-18 CA CA2961894A patent/CA2961894C/en active Active
- 2015-09-18 EP EP19206911.0A patent/EP3685832B1/en active Active
- 2015-09-18 EP EP15842612.2A patent/EP3193865B1/en active Active
- 2015-09-18 AU AU2015317330A patent/AU2015317330B2/en active Active
-
2017
- 2017-03-17 US US15/462,253 patent/US10413522B2/en active Active
-
2019
- 2019-09-13 US US16/570,180 patent/US11058665B2/en active Active
-
2021
- 2021-04-14 AU AU2021202257A patent/AU2021202257B2/en active Active
- 2021-06-11 US US17/345,572 patent/US12029717B2/en active Active
-
2023
- 2023-08-23 AU AU2023219864A patent/AU2023219864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534583A5 (enExample) | ||
| Taylor-Harding et al. | Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS | |
| EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
| PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| Delmas et al. | The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| EA201591069A1 (ru) | Лечение злокачественной опухоли гетероциклическими ингибиторами глутаминазы | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| Westhoff et al. | Targeting FOXM1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer | |
| TW201613644A (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor | |
| JP2014513136A5 (enExample) | ||
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| ATE525375T1 (de) | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 | |
| EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
| MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
| JP2015504847A5 (enExample) | ||
| SA520420909B1 (ar) | تثبيط بروتين رابط لـ creb (cbp) | |
| Yeung et al. | K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines | |
| Chan et al. | PLCɛ and the RASSF family in tumour suppression and other functions | |
| JP2018534256A5 (enExample) | ||
| Zhuang et al. | MicroRNA‐30e‐5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma | |
| JP2019512021A5 (enExample) |